WALTHAM, Mass.– Trinity Life Sciences, the leader in strategy, insights and analytics for the life sciences industry, today announces an enhancement to its HTA Vision offering that swiftly extracts relevant information from health technology assessments (HTAs) and Trinity expert analyses, streamlining the information-gathering process within any therapeutic area or drug class. By not only locating but also summarizing key information with generative AI (GenAI), HTA Vision transforms complex documents into clear, comprehensive overviews.
HTA outcomes are lengthy, complex documents that need to be quickly digested and interpreted by Global Market Access leaders in life sciences so that they can apply the learnings to day-to-day decision-making. Expert knowledge of countries, agencies, therapeutic areas and lifecycle stage are essential to provide the context necessary to arrive at actionable recommendations for a particular brand.
“Especially in the EU, market standards and complexities are increasing, which is making the environment more challenging for pharma,” explained Monica Martin de Bustamante, Senior Partner and Head of Advisory at Trinity Life Sciences. “Combining artificial intelligence with human expertise streamlines and simplifies payer decision analysis without losing the tailored interpretations and deep insights from experts on how health authorities are evaluating products.”
“Strategic decisions for clinical development and evidence generation are made by life sciences leaders on a daily basis and need to be informed by the latest market intelligence,” added Max Hunt, a Partner in Trinity Life Sciences’ Evidence, Value, Access & Pricing practice. “Trinity HTA Vision allows users to position themselves for success in a global payer landscape that can be fickle and demanding—the addition of GenAI provides users with insights on HTA drivers at their fingertips.”
